About InVivoSIM anti-human nectin-4 (Enfortumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Enfortumab making it ideal for research use. This Enfortumab biosimilar reacts human nectin-4, also known as poliovirus receptor-related protein 4 (PVRL4). Nectin-4 belongs to the nectin family of cell adhesion molecules and plays a vital role in cell-cell adhesion. Nectin-4 is primarily expressed by epithelial cells, including those of the urinary bladder, lung, and breast tissue. It is involved in various biological processes such as tissue integrity maintenance, epithelial polarization, and immune response regulation. In recent years, nectin-4 has gained considerable attention in the context of cancer therapy, with the development of enfortumab vedotin, an antibody-drug conjugate that targets nectin-4, demonstrating promising results in the treatment of certain types of advanced urothelial cancers. This Enfortumab biosimilar antibody is only the antibody portion of Enfortumab vedotin and does not contain the drug conjugate. InVivoSIM anti-human nectin-4 (Enfortumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman nectin-4 Reported ApplicationsFunctional assays ELISA Western blot FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
